FDA Allows Trials of Opdivo Combo Therapy to Resume, Signaling No New Safety Concerns
News
The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial hold in September 2017, ... Read more